1. What Due Diligence Issues Create the Highest Post-Closing Exposure?
Due diligence failures are the leading source of post-closing disputes in mergers and acquisitions transactions. The scope and rigor of your investigation directly determine what liabilities you inherit, what indemnification claims you can sustain, and whether material adverse change (MAC) defenses will hold up in litigation. Incomplete or rushed diligence often surfaces hidden environmental liabilities, undisclosed litigation, regulatory violations, or customer concentration risks that were knowable but missed. A practical example: in a recent SDNY case, a buyer discovered post-closing that the target company had failed to disclose ongoing investigations by the FDA regarding product compliance. The buyer's diligence team had reviewed regulatory filings, but they had not interviewed operations staff directly about open inquiries. The buyer's indemnification claim was weakened because the seller argued the buyer should have asked more probing questions; the court found the buyer's diligence procedures inadequate under the contract's standard of care.
How Should You Structure the Diligence Timeline and Scope?
Begin diligence early and in parallel tracks, not sequentially. Legal diligence, financial diligence, operational diligence, and tax diligence should run concurrently so that findings in one workstream inform questions in another. Set clear document production deadlines and reserve the right to conduct follow-up requests. Many buyers make the mistake of accepting the seller's initial data room as complete; instead, treat it as a starting point and issue specific requests for customer contracts, employment agreements, litigation files, regulatory correspondence, and board minutes. Your diligence team should also conduct management interviews and, where possible, speak directly with key customers and vendors. The depth of your investigation will be scrutinized in any later indemnification dispute, so document your methodology and the rationale for accepting any gaps.
What Role Does New York Court Review Play in Diligence Disputes?
If a post-closing indemnification claim proceeds to litigation in New York courts, judges will examine whether the buyer's diligence procedures met the contractual standard and whether the seller's disclosures were adequate. New York courts apply a strict materiality standard: a matter is material only if there is a substantial likelihood a reasonable investor would consider it important. This means that small or isolated compliance issues may not support an indemnification claim even if technically undisclosed. The buyer bears the burden of proving both that the matter was material and that the seller knew or should have known of it. Judges are skeptical of buyers who claim ignorance of matters that were knowable through reasonable investigation.
2. How Do Regulatory Approvals and Antitrust Exposure Affect Deal Timing and Structure?
Regulatory approval risk varies dramatically by industry and transaction size. Federal Trade Commission (FTC) review under the Hart-Scott-Rodino Act applies to transactions above a certain size threshold, and the FTC increasingly challenges mergers in healthcare, technology, and financial services. State-level approvals may also be required depending on the target's business lines. Antitrust exposure is not merely a timing issue; it can reshape deal economics or kill a transaction entirely. Underestimating regulatory risk leads buyers to commit capital and management attention to deals that later face unexpected delays or conditions. In the healthcare sector, for example, hospital mergers and acquisitions often require state attorney general approval and detailed competitive analysis that can extend timelines by months.
What Antitrust Factors Should You Evaluate Early?
Conduct a preliminary antitrust risk assessment before signing a letter of intent. Evaluate market concentration, whether the transaction would eliminate a significant competitor, customer switching costs, and the strength of barriers to entry. If the transaction raises obvious competitive concerns, the deal structure may need modification (e.g., divestitures, behavioral remedies, or geographic limitations) to obtain approval. Counsel should also assess the likelihood of state or local objections, particularly if the target operates in regulated industries or serves geographically concentrated markets. Delays in obtaining regulatory approval can trigger MAC clauses or financing conditions, so build realistic approval timelines into your deal schedule.
3. What Indemnification and Escrow Arrangements Protect Each Party?
Post-closing indemnification is the primary mechanism by which buyers recover for breaches of seller representations and warranties. The scope, dollar caps, baskets, and survival periods of indemnification provisions directly affect your actual recovery prospects. Many sellers resist robust indemnification, arguing that the buyer's due diligence should have caught all material issues. Buyers, conversely, seek broad indemnification because they know that unknown liabilities will emerge. The practical compromise is a tiered structure: a basket (threshold) below which claims are not paid, a cap (maximum recovery), a survival period (often 12 to 24 months post-closing), and an escrow holdback (typically 10 to 20 percent of purchase price) to secure the seller's obligations. Escrow arrangements vary significantly in their enforceability and administration. A poorly drafted escrow agreement can leave both parties litigating over claims that should have been straightforward.
How Do Courts in New York Interpret Indemnification Baskets and Caps?
New York courts strictly construe indemnification language and require buyers to prove that a breach falls within the defined scope and meets any contractual materiality thresholds. Baskets are interpreted as true thresholds: a buyer cannot recover for individual claims below the basket amount, and aggregate recovery is measured against the basket as a single hurdle. Caps, by contrast, are read as limits on total recovery. Courts have held that a buyer cannot circumvent a cap by characterizing multiple related breaches as separate claims. Additionally, New York courts enforce survival periods strictly: claims not asserted before the expiration date are barred, even if the underlying breach occurred before expiration. Sellers often push for short survival periods (6 to 12 months) to achieve finality; buyers resist. The practical effect is that many legitimate claims go uncompensated because the buyer did not discover the issue within the contractual window.
4. What Strategic Decisions Should You Prioritize before Signing?
The critical strategic decisions in mergers and acquisitions occur before the purchase agreement is executed. Once signed, your ability to modify terms, expand diligence, or walk away narrows dramatically. First, confirm that your financing is committed and that no material conditions remain unresolved. Second, complete preliminary diligence on the target's regulatory status, litigation exposure, and customer concentration. Third, negotiate indemnification provisions that reflect the actual risk profile of the business and the depth of your diligence. Fourth, clarify what constitutes a material adverse change and whether ordinary business fluctuations or industry-wide downturns trigger MAC rights. For healthcare transactions and other specialized sectors, counsel experienced in mergers and acquisitions within that industry is essential because deal structures and regulatory pathways vary widely. Finally, establish a realistic closing timeline and identify all regulatory approvals required upfront so that delays do not become surprises. The deal that appears attractive on paper often carries hidden complexity that emerges only after the binding commitment is made.
03 Apr, 2026
